showed in vitro synergism (CombI < 0.7) between a Bcl‐2 inhibitor and the ChT drug irinotecan and that this combination reduced tumor size in a mouse model of non‐small cell lung cancer [60]. The gene discussed is BCL2; the disease is neoplasm.